Forecast Period | 2025-2029 |
Market Size (2023) | USD 4.15 Billion |
Market Size (2029) | USD 6.29 Billion |
CAGR (2024-2029) | 7.15% |
Fastest Growing Segment | Molecular Tests |
Largest Market | Europe |
Market Overview
Global
Hospital Acquired Disease Testing Market was valued at USD 4.15 billion in 2023
and is anticipated to project impressive growth in the forecast period with a CAGR
of 7.15% through 2029. The Global Hospital Acquired Disease (HAD) Testing
Market includes diagnostic tests and technologies designed to identify
infections acquired by patients during their hospital stays, known as
healthcare-associated infections (HAIs). These infections present significant
challenges to healthcare systems globally, impacting patient outcomes,
healthcare costs, and hospital operations. The market is experiencing
consistent growth driven by increasing HAI rates, advancements in technology,
and rising healthcare expenditures worldwide. Key industry players are focusing
on innovation and strategic partnerships to tackle challenges and leverage
emerging opportunities in this dynamic healthcare sector. As awareness of
infection control grows and healthcare providers prioritize patient safety,
there is a growing demand for advanced diagnostic solutions, which is expected
to fuel further market expansion globally.
Key Market Drivers
Rising Prevalence of
Hospital-Acquired Infections (HAIs)
The
rising prevalence of hospital-acquired infections (HAIs) is a major driver of
growth in the Global Hospital Acquired Disease Testing Market. HAIs are
infections that patients acquire while receiving treatment for medical or
surgical conditions within a healthcare setting. The increase in these
infections has significant implications for patient outcomes, healthcare costs,
and public health, thereby fueling the demand for advanced diagnostic testing
solutions. The incidence of HAIs, such as methicillin-resistant Staphylococcus
aureus (MRSA), Clostridium difficile, and vancomycin-resistant Enterococci
(VRE), has been rising globally. Factors contributing to this increase include
the higher complexity of medical procedures, increased use of invasive devices,
and the aging population with multiple comorbidities. The growing prevalence of
these infections necessitates efficient and accurate diagnostic testing to
identify and manage HAIs promptly. HAIs pose a significant public health
challenge due to their association with increased morbidity and mortality
rates. The ability to rapidly detect and control HAIs is crucial to preventing
outbreaks within healthcare facilities. This urgent need drives the demand for
advanced diagnostic technologies capable of identifying pathogens with high
sensitivity and specificity.
HAIs
lead to longer hospital stays, additional treatments, and the need for more
intensive care, significantly raising healthcare costs. Hospitals are under
pressure to reduce these costs by implementing effective infection control
measures, including advanced diagnostic testing. Early and accurate diagnosis
of HAIs can help in reducing the duration of hospital stays and associated
costs, making the investment in diagnostic testing economically beneficial. In
many regions, healthcare facilities face financial penalties for high rates of
HAIs. For instance, in the United States, the Centers for Medicare &
Medicaid Services (CMS) reduce reimbursements to hospitals with high rates of
certain HAIs. These penalties incentivize hospitals to invest in reliable
diagnostic tools to lower their HAI rates and avoid financial losses. Regulatory
bodies worldwide have established stringent guidelines for the reporting and
surveillance of HAIs. Compliance with these regulations requires robust
diagnostic testing to accurately track infection rates. The need to adhere to
these guidelines propels the demand for advanced diagnostic tests that can
provide precise and timely results. Healthcare facilities are mandated to
implement comprehensive infection control programs that include routine HAI
screening and monitoring. Advanced diagnostic testing is a cornerstone of these
programs, enabling early detection and isolation of infected patients to
prevent the spread of infections.
Technological
advancements in diagnostic testing, such as molecular diagnostics and rapid
antigen tests, offer significant improvements in the speed and accuracy of HAI
detection. These technologies allow for the early identification of pathogens,
leading to timely treatment and better patient outcomes. The increasing
prevalence of HAIs drives the adoption of these advanced technologies in
healthcare settings. The rising prevalence of HAIs also drives the shift
towards personalized medicine, where diagnostic testing plays a critical role
in tailoring treatments to individual patient needs. Advanced diagnostics can
identify specific strains and resistance profiles of pathogens, guiding
targeted therapy and improving treatment efficacy. There is a growing emphasis
on educating healthcare professionals about the importance of early detection
and management of HAIs. Training programs and continuing medical education
(CME) courses highlight the role of advanced diagnostic testing in infection
control, driving its adoption in clinical practice. Patients and advocacy
groups are increasingly aware of the risks associated with HAIs and demand high
standards of care. This heightened awareness compels healthcare providers to
invest in state-of-the-art diagnostic testing to ensure patient safety and meet
public expectations.
The
rising prevalence of hospital-acquired infections is a significant driver of
growth in the Global Hospital Acquired Disease Testing Market. The increased
incidence of HAIs, their economic impact on healthcare systems, regulatory and
compliance pressures, technological advancements in diagnostic testing, and
rising awareness among healthcare professionals and patients collectively
create a robust demand for advanced diagnostic solutions. These factors
underscore the critical importance of early and accurate detection of HAIs,
driving the continuous innovation and adoption of diagnostic technologies to
enhance patient outcomes and healthcare efficiency.
Technological Advancements in
Diagnostic Testing
Technological
advancements in diagnostic testing play a pivotal role in driving the growth of
the Global Hospital Acquired Disease (HAD) Testing Market. These advancements
encompass innovations in molecular diagnostics, automation, digital health
integration, and next-generation sequencing (NGS), among others.
Polymerase
Chain Reaction (PCR) and its advanced form, real-time PCR, are cornerstone
technologies in molecular diagnostics. These methods amplify small amounts of
DNA or RNA to detectable levels, providing high sensitivity and specificity in
identifying pathogens responsible for HAIs. The ability to quickly and
accurately identify bacterial, viral, and fungal infections helps in early
diagnosis and effective treatment, reducing the spread of infections within
healthcare facilities. Innovations such as Loop-Mediated Isothermal
Amplification (LAMP) offer rapid and cost-effective alternatives to traditional
PCR. These technologies do not require complex thermal cycling equipment and
can deliver results quickly, making them suitable for point-of-care (POC)
settings. The accessibility and efficiency of these tests drive their adoption,
especially in resource-limited environments.
Next-Generation
Sequencing (NGS) allows for comprehensive analysis of pathogen genomes,
providing detailed information about their genetic makeup and resistance
profiles. This technology can detect multiple pathogens simultaneously,
identify novel or emerging strains, and provide insights into microbial
communities. Such detailed profiling is invaluable in managing complex HAIs and
tailoring treatment strategies. Recent advancements in NGS have significantly
reduced the time required to sequence and analyze genetic material. Rapid
turnaround times mean that healthcare providers can make informed decisions
more quickly, improving patient outcomes and preventing the further spread of
infections. Automation in diagnostic laboratories has revolutionized the
processing of samples. Automated platforms can handle large volumes of tests
with minimal human intervention, ensuring consistency, reducing errors, and
speeding up the diagnostic process. This efficiency is particularly crucial in
hospital settings where timely diagnosis of HAIs is essential to prevent
outbreaks. High-throughput screening technologies enable the simultaneous
processing of numerous samples, facilitating large-scale surveillance and
monitoring of HAIs. This capability is vital during outbreaks or in
high-incidence areas, allowing for swift identification and containment of
infections.
The
development of rapid diagnostic tests for POC use has transformed the landscape
of HAI management. These tests provide immediate results at the patient's
bedside, in outpatient clinics, or in remote locations, enabling prompt
clinical decisions. Innovations in POC testing devices, including portable and
user-friendly formats, enhance their utility and adoption in diverse healthcare
settings. Multiplex POC tests that can detect multiple pathogens or resistance
genes in a single assay are gaining traction. These tests reduce the need for
multiple separate tests, saving time and resources while providing
comprehensive diagnostic information. The integration of diagnostic testing
with electronic health records (EHR) systems facilitates seamless data flow and
real-time monitoring of patient health. Automated data entry and analysis
reduce administrative burdens, minimize errors, and enhance the efficiency of
infection control programs. Advanced data analytics and AI technologies are
increasingly being integrated into diagnostic workflows. AI algorithms can
analyze vast amounts of diagnostic data, identify patterns, predict outbreaks,
and support clinical decision-making. These capabilities improve the accuracy
of diagnoses, optimize treatment plans, and enhance overall patient care.
Technological
advancements in diagnostic testing are a primary driver of growth in the Global
Hospital Acquired Disease Testing Market. Enhanced sensitivity and specificity
of molecular diagnostics, the comprehensive capabilities of next-generation
sequencing, automation and high-throughput systems, innovations in
point-of-care testing, and integration with digital health technologies
collectively improve the efficiency, accuracy, and speed of HAI diagnostics.
These advancements enable healthcare providers to detect and manage HAIs more
effectively, reducing infection rates, improving patient outcomes, and driving
the continuous expansion of the diagnostic testing market.
Growing Awareness and
Education
The
growing awareness and education regarding hospital-acquired infections (HAIs)
are key drivers of growth in the Global Hospital Acquired Disease (HAD) Testing
Market. This heightened awareness among healthcare professionals, patients, and
the general public fuels the demand for advanced diagnostic solutions, improves
infection control practices, and encourages investment in innovative
technologies.
Continuing
Medical Education (CME) programs and professional development courses are
pivotal in keeping healthcare professionals updated on the latest advancements
in HAI diagnostics and management. These programs provide critical information
on new diagnostic technologies, best practices in infection control, and the
latest research findings. Enhanced knowledge and skills among healthcare
workers lead to better diagnostic accuracy and improved patient care, driving
the demand for advanced diagnostic tools. Hospitals and healthcare facilities
are increasingly implementing comprehensive infection control training for
their staff. These training programs emphasize the importance of early and
accurate detection of HAIs, proper specimen collection techniques, and
adherence to diagnostic protocols. Well-trained healthcare professionals are
more likely to utilize advanced diagnostic tests, contributing to market
growth.
Public
health organizations, governments, and non-profits are conducting awareness
campaigns to educate the public about the risks and consequences of HAIs. These
campaigns highlight the importance of early detection and prevention,
encouraging patients to demand high standards of care and prompt diagnostic
testing. Increased public awareness leads to greater acceptance and utilization
of HAD testing in healthcare settings. Patient advocacy groups play a
significant role in raising awareness about HAIs and advocating for safer
healthcare practices. These groups often push for the adoption of advanced
diagnostic technologies and improved infection control measures. Their efforts
contribute to a higher demand for reliable and efficient diagnostic tests, as
patients become more informed and proactive about their healthcare. Governments
and health authorities worldwide are implementing stringent regulations and
guidelines to combat HAIs. These regulations often include mandatory reporting
and surveillance of infection rates, necessitating the use of advanced
diagnostic tests. Compliance with these guidelines drives hospitals and
healthcare providers to invest in state-of-the-art diagnostic technologies. Healthcare
institutions are adopting policies that prioritize infection control and
prevention. Institutional policies often mandate regular HAI screening and
monitoring, the implementation of best practices, and the use of cutting-edge
diagnostic tools. Such policies ensure that healthcare facilities are
well-equipped to handle HAIs, driving the growth of the diagnostic testing
market.
Diagnostic
companies are actively collaborating with healthcare institutions to provide
training and education on the use of their products. Workshops, webinars, and
hands-on training sessions help healthcare professionals understand the
benefits and applications of advanced diagnostic technologies. This direct
engagement fosters trust and encourages the adoption of new diagnostic
solutions. Manufacturers of diagnostic tests are employing informative
marketing strategies to educate healthcare providers about the capabilities and
advantages of their products. Detailed product information, case studies, and
success stories are shared through various channels, including conferences,
medical journals, and online platforms. This education-driven marketing
approach helps in building awareness and driving market demand. Partnerships
between diagnostic companies and academic institutions facilitate research and
development of new diagnostic technologies. These collaborations often result
in the incorporation of advanced diagnostic methods into medical curricula,
ensuring that future healthcare professionals are well-versed in the latest
technologies. This integration drives long-term growth by creating a
knowledgeable and skilled workforce. The dissemination of research findings
through academic publications and conferences enhances the overall knowledge
base regarding HAIs and diagnostic technologies. These platforms provide
opportunities for sharing best practices, discussing challenges, and showcasing
innovations. The resulting increase in awareness and knowledge contributes to
the wider adoption of advanced diagnostic tests.
Growing
awareness and education are crucial drivers of growth in the Global Hospital
Acquired Disease Testing Market. Increased awareness among healthcare
professionals, public awareness and patient advocacy, regulatory and
institutional initiatives, educational outreach by diagnostic companies, and
integration with academic research and curriculum collectively enhance the
demand for advanced diagnostic solutions. These factors ensure that healthcare
providers are well-equipped to detect and manage HAIs effectively, leading to
improved patient outcomes and driving the continuous expansion of the
diagnostic testing market.
Download Free Sample Report
Key Market Challenges
High Costs and Limited Budget
Allocation
The
advanced technologies and equipment required for effective HAD testing, such as
molecular diagnostics and automated systems, are often costly. This high
initial investment can be a significant barrier for many healthcare facilities,
particularly in developing regions where budget constraints are more
pronounced.
Beyond
the initial acquisition, the ongoing costs associated with consumables,
maintenance, and technical support for diagnostic equipment can strain hospital
budgets. The need for continuous replenishment of reagents and test kits, along
with regular calibration and servicing of machines, adds to the financial
burden.
Healthcare
facilities must prioritize their spending, often directing funds towards
immediate patient care needs, infrastructure, and other critical areas. This
prioritization can result in limited budget allocation for diagnostic testing,
restricting the adoption and utilization of advanced HAD testing technologies.
Regulatory and Compliance
Challenges
Navigating
the complex regulatory landscape for diagnostic tests can be challenging.
Different regions have varying regulatory requirements, approvals, and
compliance standards, which can delay the introduction of new diagnostic
products into the market. Companies must invest significant time and resources
to meet these diverse regulatory demands.
Ensuring
that diagnostic tests meet stringent quality control and performance standards
is essential for regulatory approval. This involves rigorous testing,
validation, and documentation processes, which can be time-consuming and
costly. Any failure to meet these standards can result in delays or rejections,
impacting market growth.
Regulatory
guidelines for diagnostic tests, especially for emerging technologies like
molecular diagnostics, are continually evolving. Keeping pace with these
changes requires ongoing monitoring and adaptation by manufacturers, adding to
the complexity and cost of bringing new products to market.
Technical and Operational
Challenges
The
implementation and operation of advanced diagnostic testing require a highly
skilled workforce. There is a shortage of trained laboratory technicians,
molecular biologists, and other specialized personnel needed to conduct and
interpret complex tests. This skills gap can hinder the effective utilization
of HAD testing technologies.
Integrating
new diagnostic technologies with existing hospital information systems and
workflows can be challenging. Compatibility issues, data integration problems,
and the need for additional training can slow down the adoption process.
Effective integration is crucial for ensuring seamless operations and
maximizing the benefits of advanced diagnostics.
Many
healthcare facilities, particularly in low-resource settings, lack the
necessary infrastructure to support advanced diagnostic testing. This includes
inadequate laboratory space, insufficient power supply, and lack of access to
reliable internet for data transmission and analysis. These limitations
restrict the deployment and use of sophisticated diagnostic tools.
Key Market Trends
Integration of Artificial
Intelligence (AI) and Machine Learning (ML) in Diagnostic Testing
The
integration of AI and ML in diagnostic testing is revolutionizing the
identification and management of hospital-acquired diseases (HAD). Advanced
algorithms can analyze vast amounts of patient data to predict the likelihood
of infections, identify patterns, and provide decision support for clinicians.
These technologies enable more accurate and timely diagnoses, reducing the
incidence and severity of HAIs.
AI-driven
automation in laboratory processes enhances the efficiency and accuracy of
diagnostic tests. Automated systems can handle high volumes of tests with
minimal human intervention, reducing errors and turnaround times. This is
particularly critical in managing HAIs, where rapid diagnosis and response are
essential to prevent outbreaks.
AI
and ML facilitate personalized medicine by analyzing genetic, phenotypic, and
clinical data to tailor treatments to individual patients. In the context of
HAIs, this means that therapies can be customized based on the specific
pathogen strain and the patient's unique characteristics, improving treatment
outcomes and reducing hospital stays.
Expansion of Point-of-Care
(POC) Testing
Point-of-care
testing (POC) is transforming the HAD testing market by bringing diagnostics
closer to the patient. POC tests provide rapid results at the bedside or in
outpatient settings, enabling immediate clinical decisions. This is crucial in
managing HAIs, where early detection and intervention can significantly reduce
transmission and improve patient outcomes.
Innovations
in POC testing technology are driving market growth. Portable, user-friendly
devices equipped with advanced diagnostic capabilities allow for accurate
detection of pathogens in various settings. The development of multiplex POC
tests, which can simultaneously detect multiple pathogens, further enhances
their utility in healthcare facilities.
POC
testing reduces the need for centralized laboratory infrastructure and
associated costs. By delivering quick results, it minimizes patient wait times
and hospital stays, optimizing resource utilization. This cost-effectiveness is
particularly beneficial for healthcare systems operating under budget
constraints, making POC testing an attractive option for widespread adoption.
Growing Emphasis on
Antimicrobial Stewardship and Infection Control
There
is an increasing emphasis on antimicrobial stewardship and infection control
driven by regulatory frameworks and healthcare policies. Governments and health
organizations worldwide are implementing guidelines and mandates to combat
antimicrobial resistance (AMR) and HAIs. These initiatives encourage the
adoption of advanced diagnostic tests to accurately identify pathogens and
their resistance profiles, guiding appropriate treatment strategies.
Substantial
investments in R&D focused on infection control and antimicrobial
stewardship are driving innovation in the HAD testing market. Companies and
academic institutions are developing new diagnostic technologies and
methodologies to detect infections more rapidly and accurately. These
advancements are crucial in managing HAIs and mitigating the spread of
resistant pathogens.
Increasing
awareness about the importance of antimicrobial stewardship and infection
control among healthcare professionals and the public is promoting the use of
advanced diagnostic tests. Educational programs and awareness campaigns
highlight the role of accurate and timely diagnostics in preventing the misuse
of antibiotics and controlling the spread of infections, further driving market
growth.
Segmental Insights
Test Type Insights
Based
on the category of Test Type, the molecular tests segment emerged as the
dominant in the global market for Hospital Acquired Disease Testing in 2023. Polymerase
Chain Reaction (PCR) and real-time PCR are widely used molecular techniques
that allow for the rapid and specific detection of pathogens. These
technologies have evolved to offer high-throughput capabilities, automation,
and reduced turnaround times, making them indispensable in hospital settings. Next-generation
sequencing provides comprehensive data on pathogen genomes, enabling precise
identification and characterization of infectious agents. The ability to detect
multiple pathogens simultaneously and identify genetic markers of antimicrobial
resistance is a significant advantage. Techniques like Loop-mediated Isothermal
Amplification (LAMP) offer rapid and cost-effective alternatives to traditional
PCR, enhancing the accessibility of molecular testing in various healthcare
settings.
Molecular
tests are known for their superior accuracy and sensitivity compared to
traditional methods like culture or immunoassays. They can detect low levels of
pathogens and identify infections at early stages, which is crucial for timely
intervention and infection control in hospitals. The rising incidence of HAIs,
such as methicillin-resistant Staphylococcus aureus (MRSA), Clostridium
difficile, and multidrug-resistant Gram-negative bacteria, necessitates
effective and reliable diagnostic tools. Molecular tests can rapidly identify
these pathogens and their resistance profiles, aiding in appropriate treatment
and containment measures. These factors are expected to drive the growth of
this segment.
Product Type Insights
The
consumables pharmacies segment is projected to experience rapid growth during
the forecast period. Consumables, such as reagents, test kits, and assay
plates, are integral to the daily operations of diagnostic laboratories. Unlike
durable equipment, which has a long lifespan, consumables are used on a
per-test basis, creating a recurring demand. This consistent need for
replenishment ensures a steady and growing market for consumables. Innovations
in biochemistry and molecular biology have led to the development of highly
sensitive and specific consumables. Advanced reagents and assay kits enhance
the accuracy and reliability of HAD testing, driving their adoption in clinical
settings. Manufacturers are developing specialized consumables tailored for
specific pathogens and testing methods. Customizable kits that cater to the
unique requirements of different hospital laboratories help improve the
efficiency and effectiveness of HAD diagnostics.
Consumables
are essential across various test types, including molecular tests (PCR, NGS),
immunoassays, and culture-based methods. Their universal applicability makes
them a critical component in the HAD testing workflow, regardless of the
diagnostic technology used. Consumables are subject to stringent quality
control and regulatory standards to ensure their efficacy and safety. Companies
producing these consumables must adhere to guidelines set by regulatory bodies
like the FDA, EMA, and ISO standards. This compliance ensures that only
high-quality products are available in the market, fostering trust and
widespread adoption. These factors collectively contribute to the growth of
this segment.
Download Free Sample Report
Regional Insights
Europe
emerged as the dominant in the global Hospital Acquired Disease Testing market
in 2023, holding the largest market share in terms of value. Europe boasts some
of the world's most advanced healthcare systems, characterized by high-quality
hospital facilities, advanced diagnostic laboratories, and extensive healthcare
networks. Countries like Germany, the UK, France, and the Nordic nations have
robust healthcare systems with widespread access to advanced medical
technologies. This infrastructure supports the widespread adoption of clinical
chemistry testing for hospital-acquired diseases (HAD). European countries have
stringent regulatory standards for healthcare practices and diagnostic testing,
overseen by bodies such as the European Medicines Agency (EMA) and national
regulatory authorities. These frameworks ensure the reliability and accuracy of
clinical chemistry tests, fostering trust and adoption among healthcare
providers. Additionally, the European Union’s focus on patient safety and
quality of care drives the demand for precise and effective HAD testing.
Europe
is home to numerous leading biotech and pharmaceutical companies that are at
the forefront of innovation in diagnostic testing. The region's emphasis on
research and development has led to the creation of advanced clinical chemistry
assays and instruments, which are critical for detecting and managing
hospital-acquired infections. Innovations in automation, high-throughput
screening, and point-of-care testing have significantly enhanced the efficiency
and scope of clinical chemistry tests. Hospital-acquired infections (HAIs)
remain a significant concern in European hospitals, necessitating effective
testing and monitoring solutions. The high incidence of HAIs in Europe, driven
by factors such as aging populations, extensive hospital stays, and invasive
procedures, has led to increased utilization of clinical chemistry tests. These
tests play a crucial role in diagnosing and managing infections, thus reducing
morbidity and mortality rates associated with HAIs.
Recent Developments
- In
February 2023 - Mylab Discovery Solutions and Thermo Fisher Scientific have
entered into a strategic partnership to launch RT-PCR kits for infectious
diseases in India. Thermo Fisher Scientific, the global leader in scientific
services, and Mylab, a premier biotech company in India, announced their
collaboration to design and develop RT-PCR kits targeting infectious diseases
such as Multi-Drug Resistant Tuberculosis (MTB MDR), Hepatitis B Virus (HBV),
Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and genetic
analysis (HLA B27), as well as other significant public health diseases.
Key Market Players
- bioMérieux
SA
- Abbott Laboratories Inc.
- F. Hoffmann-La Roche Ltd.
- Siemens Healthcare Private Limited
- Becton, Dickinson and Company (BD)
- Bioscience, Inc. (Monera Technologies)
- QIAGEN N.V.
- Thermo Fisher Scientific Inc
- Hologic, Inc.
- Meridian Bioscience, Inc
|
By
Test Type
|
By
Infection Type
|
By
Product
|
By
Type
|
By
Region
|
|
|
- UTI
- Pneumonia
- Surgical
Site Infection
- Blood
Stream Infections
- Others
|
|
|
- North
America
- Europe
- Asia
Pacific
- South
America
- Middle
East & Africa
|
Report Scope:
In this report, the Global Hospital Acquired
Disease Testing Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- Hospital Acquired Disease Testing Market, By Test Type:
o Molecular
o Conventional
- Hospital Acquired Disease Testing Market, By Infection Type:
o UTI
o Pneumonia
o Surgical Site Infection
o Blood Stream Infections
o Others
- Hospital Acquired Disease Testing Market, By Product:
o Consumables
o Instruments
- Hospital Acquired Disease Testing Market, By Type:
o Blood Tests
o Urinalysis
- Hospital Acquired Disease Testing Market, By
Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Hospital
Acquired Disease Testing Market.
Available Customizations:
Global Hospital Acquired Disease Testing market report
with the given market data, Tech Sci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Hospital
Acquired Disease Testing Market is an upcoming report to be released soon. If
you wish an early delivery of this report or want to confirm the date of
release, please contact us at [email protected]